OIG Approves Manufacturer-Funded Rare Disease Patient Assistance Program, Flags Two-Year IRA Review

The U.S. Department of Health and Human Services Office of Inspector General (搜索)搜索该词条 (OIG) has approved a proposed arrangement in which a nonprofit, tax-exempt charitable organization would provide health insurance premium assistance and copayment assistance to patients with certain rare and chronic diseases, funded in part by pharmaceutical manufacturers. Published on August 21 as Advisory Opinion 26-17, the opinion is notable less for its ultimate conclusion than for a footnote in which OIG referenced the Inflation Reduction Act (搜索)搜索该词条's (IRA's) Part D redesign provisions and reserved the right to seek additional data in approximately two years to determine whether rescission, modification, or termination of the favorable opinion may be warranted.

The requestor provided data demonstrating that the covered diseases impose extraordinary financial burdens on patients, generating per-patient, per-year costs of up to $600,000 per year. Most products used to treat the diseases are reimbursable under Medicare Part B, not Part D.

The Proposed Arrangement

Under the Proposed Arrangement, the requestor proposes to establish or expand disease-specific funds that would provide both health insurance premium assistance and copayment and coinsurance assistance for prescription medications. Each Disease Fund would include a premium-assistance component and a copayment-and-coinsurance assistance component, with beneficiaries receiving assistance on a first-come, first-served basis pursuant to a reasonable, verifiable, and uniformly administered financial need policy.

Several structural features define the arrangement. Disease Funds would be defined by widely recognized clinical standards, such as ICD codes, and would cover a broad spectrum of products. Copayment assistance would not be limited to high-cost or specialty drugs; eligible patients could receive assistance covering all FDA-approved prescription medications for the diseases, including generics and bioequivalent drugs. For the one disease with only one FDA-approved treatment, the fund would also support prescription drugs used to manage the disease, its symptoms, and treatment side effects.

Funding would come from multiple sources, including pharmaceutical manufacturers whose drugs are used to treat the covered diseases, as well as financially disinterested donors. While donors could earmark contributions for a specific Disease Fund, the requestor would retain absolute discretion over the use of funds within that fund. Patients would choose their healthcare providers and products before applying for assistance and would remain free to change providers or products at any time.

OIG's Anti-Kickback Statute Analysis

OIG concluded that the Proposed Arrangement implicates the federal Anti-Kickback Statute (AKS) because pharmaceutical manufacturers would provide remuneration, in the form of copayment and premium subsidies, through the requestor to patients diagnosed with a disease that can be treated by one of the manufacturers' products. According to OIG, such assistance could induce the purchase or ordering of federally reimbursable drugs manufactured by contributing companies.

Despite this, OIG determined that the arrangement presents sufficiently low risk of fraud and abuse based on a combination of factors. The requestor would not provide donors with data that would allow them to correlate their donations with the use of their products. Assistance would be awarded on a first-come, first-served basis without regard to a patient's provider, drug manufacturer, or pharmacy. No manufacturer would exercise control over the requestor or the allocation of Disease Fund resources. Disease Funds would be defined by widely recognized clinical standards and cover a broad spectrum of products, reducing the risk that any fund functions as a proxy for a single manufacturer's product. Copayment assistance would cover all FDA-approved prescription medications, including generics, reducing steering risk.

OIG also recognized that the assistance could increase access to care for patients with rare and chronic diseases who may otherwise be unable to afford needed treatment. The agency reiterated its longstanding position that independent charitable PAPs can play an important safety-net role for financially needy patients, but must remain independent of pharmaceutical manufacturer influence and must not "function as a conduit for payments by the pharmaceutical manufacturer to patients."

Beneficiary Inducements CMP Determination

OIG reached a different conclusion under the Beneficiary Inducements Civil Monetary Penalty (CMP) Law. Because the requestor is not a provider, practitioner, or supplier, and because assistance would be available without regard to a beneficiary's choice of provider, practitioner, or supplier, OIG concluded that the proposed arrangement would not be likely to influence such a selection and therefore would not constitute grounds for sanctions under the Beneficiary Inducements CMP.

The Inflation Reduction Act's Part D Redesign

Perhaps the most significant aspect of Advisory Opinion 26-17 is OIG's explicit connection of the IRA's Part D cost-sharing reforms to its fraud and abuse analysis. OIG noted that recent IRA reforms eliminated Part D catastrophic cost sharing and imposed a $2,000 annual cap on Part D out-of-pocket spending, changes that could affect the demand for manufacturer-funded premium and cost-sharing assistance programs.

As a result, OIG stated that it may seek additional information from the organization approximately two years after issuance of the opinion, including non-patient-identifiable data regarding donors, the allocation of donations, and the distribution of assistance. OIG explained that this information could help confirm that the program is operating as certified and allow the agency to assess whether its favorable analysis remains appropriate once the arrangement has been fully implemented and the effects of the IRA can be more fully evaluated.

OIG's position is significant for several reasons. It signals that OIG is actively monitoring how the IRA's Part D redesign affects the PAP landscape. It introduces a temporal element into the analysis, suggesting that factors supporting a favorable advisory opinion today may change if associated market conditions change. And it suggests that OIG views the IRA's structural changes to Part D cost-sharing as a variable that could fundamentally alter the justification for manufacturer-funded cost-sharing subsidies.

Implications for Manufacturers and PAP Operators

For pharmaceutical manufacturers and charitable organizations, Advisory Opinion 26-17 reinforces the importance of maintaining a meaningful separation between donors and patient assistance decisions. OIG's favorable opinion rested heavily on the requesting organization's independence, broad disease-fund definitions, product-neutral assistance, objective financial-need criteria, and safeguards preventing donors from obtaining information that could be used to correlate contributions with utilization of their products.

The opinion also underscores the importance of ensuring that program operations align with written policies. Organizations considering similar arrangements should evaluate not only the design of their programs but also how funding decisions, eligibility determinations, donor communications, and reporting practices are implemented in practice. As with all advisory opinions, Advisory Opinion 26-17 is limited to the requestor and the specific facts and circumstances presented, but it provides important insight regarding OIG's evolving perspective on the interplay between the IRA's Part D redesign and manufacturer-funded patient assistance programs.